4D Molecular Therapeutics Inc (NASDAQ: FDMT) kicked off on Monday, down -3.64% from the previous trading day, before settling in for the closing price of $7.97. Over the past 52 weeks, FDMT has traded in a range of $2.23-$12.34.
A company in the Healthcare sector has dropped its sales by -9.89% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -9.35%. With a float of $52.01 million, this company’s outstanding shares have now reached $57.14 million.
4D Molecular Therapeutics Inc (FDMT) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of 4D Molecular Therapeutics Inc is 8.97%, while institutional ownership is 65.83%. The most recent insider transaction that took place on Dec 20 ’25, was worth 3,377. In this transaction VP, Finance and Controller of this company sold 389 shares at a rate of $8.68, taking the stock ownership to the 46,218 shares. Before that another transaction happened on Dec 16 ’25, when Company’s Chief Legal Officer sold 1,635 for $10.90, making the entire transaction worth $17,822. This insider now owns 3,594 shares in total.
4D Molecular Therapeutics Inc (FDMT) Latest Financial update
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.9 earnings per share (EPS), lower than consensus estimate (set at -0.84) by -0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.93 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.35% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.65% during the next five years compared to -9.89% drop over the previous five years of trading.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
Take a look at 4D Molecular Therapeutics Inc’s (FDMT) current performance indicators. Last quarter, stock had a quick ratio of 8.42. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3656.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.94, a number that is poised to hit -0.53 in the next quarter and is forecasted to reach -3.48 in one year’s time.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
Let’s dig in a bit further. During the last 5-days, its volume was 0.82 million. That was inferior than the volume of 0.88 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 5.95%.
During the past 100 days, 4D Molecular Therapeutics Inc’s (FDMT) raw stochastic average was set at 33.52%, which indicates a significant increase from 0.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.78 in the past 14 days, which was higher than the 0.71 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.47, while its 200-day Moving Average is $6.40. However, in the short run, 4D Molecular Therapeutics Inc’s stock first resistance to watch stands at $7.84. Second resistance stands at $8.00. The third major resistance level sits at $8.08. If the price goes on to break the first support level at $7.59, it is likely to go to the next support level at $7.51. The third support level lies at $7.35 if the price breaches the second support level.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Key Stats
The company with the Market Capitalisation of 438.80 million has total of 57,135K Shares Outstanding. Its annual sales at the moment are 40 K in contrast with the sum of -160,870 K annual income. Company’s last quarter sales were recorded 90 K and last quarter income was -56,880 K.
